Research and Development

Showing 15 posts of 9596 posts found.

TREND: Rare disease, cancer drugs will drive pharma M&A’s, growth

March 29, 2016 Manufacturing and Production, Research and Development, Sales and Marketing M&A, MA, Orphan Drugs, cancer drugs

Moody’s Investor Service lowered its growth outlook for the global pharma sector but maintained the mergers and acquisitions in the …
novo_flag

Novo Nordisk breaks ground on new $2 billion production facility in North Carolina

March 29, 2016 Manufacturing and Production, Research and Development $2 billion, Clayton, Novo, Novo Nordisk, building, diabetes, nordisk, north carolina, production facility

Novo Nordisk has begun work on a new $2 billion production facility in Clayton, North Carolina, which will produce active …
shutterstock_92671375

US FDA issues observations for Natco Pharma’s Indian plants

March 29, 2016 Manufacturing and Production, Research and Development, Sales and Marketing

Shares in India-based Natco Pharma (BOM: 524816) dropped on the Bombay Stock Exchange following news the US Food and Drug …

Portola Pharma stock drops on dismal Phase III trial results for blood-clot drug

March 29, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Portola Pharmaceuticals, blood clot drug, drug trial, phase III

Shares in Portola Pharmaceuticals (Nasdaq: PTLA) dropped after the company reported disappointing late-stage trial results for its blood clotting drug. …
brintellix

FDA issues CRL for Takeda/Lundbeck’s Brintellix

March 29, 2016 Manufacturing and Production, Research and Development Lundbeck, Takeda, brintellix

Takeda and Lundbeck have received a complete response letter from the US Food and Drug Administration (FDA) for the supplemental …
logo

Phase III trial initiated for enzalutamide in treatment of prostate cancer

March 24, 2016 Research and Development Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer

Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate …
msd

MSD teams up with Harvard to develop new leukaemia treatments

March 24, 2016 Medical Communications, Research and Development AML, Harvard, MSD, leukaemia

MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …

EMA to review Pfizer’s Xeljanz for patients with rheumatoid arthritis

March 24, 2016 Research and Development, Sales and Marketing EMA, Pfizer, Xeljanz, approval, authorisation, marketing, review, rheumatoid arthritis

Pfizer (NYSE: PFE) has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) …
teva_copy

Teva announces FDA approval for asthma injection, Cinqair

March 24, 2016 Research and Development, Sales and Marketing FDA, Teva, approval, asthma, cinqair

The US Food and Drug Administration has approved Cinqair (reslizumab), an injection for patients with severe asthma developed by Teva …

Biotech Micreos appoints CMO to lead clinical development of antibiotic alternative

March 23, 2016 Research and Development

Dr Johan Frieling has been appointed as the new chief medical officer of Dutch biotech company Micreos, at a pivotal …
sanofi_pasteur_scientist

Sanofi and Regeneron meet endpoint in Phase III Praluent study

March 23, 2016 Research and Development Regeneron, Sanofi, endpoint, escape, hefh, odyssey, phase 3, phase III, positive, praulent, trial

Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …
bms_good

Bristol-Myers Squibb to acquire Padlock Therapeutics for up to $600m

March 23, 2016 Research and Development, Sales and Marketing Bristol-Myers Squibb, Padlock Therapeutics, rheumatoid arthritis

Bristol-Myers Squibb is to acquire Massachusetts-based auto-immune disease specialist Padlock Therapeutics in a deal worth up to $600 million. The …
brilinta

AstraZeneca’s Brilinta fails to best aspirin in treating stroke patients

March 23, 2016 Research and Development AstraZeneca, Brilinta, stroke

AstraZeneca has announced top-line results from the Phase III SOCRATES trial, confirming that twice-daily doses of its drug Brilinta (ticagrelor) failed …
sovaldi-web

Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute

March 23, 2016 Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi

Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …
eli_lilly

FDA approves Lilly’s plaque psoriasis drug Taltz

March 23, 2016 Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …
The Gateway to Local Adoption Series

Latest content